PDGFRB and breast cancer: The inhibition of AKT activation by Imatinib is consistent with its known mode of action on upstream growth factor receptors; for instance, Imatinib has been shown to inhibit PDGFR-β in BC cells, leading to attenuation of PI3K/AKT signaling (39).